Christopher M. Starr
Director · Monopar Therapeutics
IndividualSelling only5 10b5-1 trades
- 2025
- Oct 5, 2026
- 2
Filings (90d)
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Christopher M. Starr files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Chandler Robinson - $2.56M in MNPR purchases and sales in the last 12 months
- Kim R. Tsuchimoto - $911K in MNPR purchases and sales in the last 12 months
- Raymond Anderson - $703K in MNPR purchases and sales in the last 12 months
- Patrice Rioux - $111 in MNPR purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Christopher M. Starr?
Christopher M. Starr is a corporate insider, tracked as Director of Monopar Therapeutics (MNPR). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Christopher M. Starr submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Christopher M. Starr been buying or selling stock?
Recorded transactions: 0 open-market purchases and 4 open-market sales ($1.33M) across all tracked filings.
